Furthermore, we recently demonstrated that Myo1g has the potential for use as a high-risk marker in pediatric ALL.Here, we have demonstrated the potential utility of these monoclonal antibodies in patient samples. This evidence concerns the gene MYO1G and acute lymphoblastic leukemia.